FDA Peptide Regulation in 2026 - What Changed for BPC-157 and TB-500

September 28, 2026

The regulatory status of BPC-157 has shifted several times since 2023. For anyone trying to understand whether this peptide is legal, approved, or available through a pharmacy, the short answer is: it depends on which month you check. The longer answer involves the FDA's bulk drug substance categories, a contentious advisory committee vote, and a political intervention that did not actually resolve the underlying question.

The Category 2 Classification (September 2023)

In September 2023, the FDA placed BPC-157 on its Category 2 list of bulk drug substances. Category 2 is reserved for substances the agency considers to raise significant safety concerns when used in compounding. Placement on this list effectively prohibited 503B outsourcing facilities from producing BPC-157 for patients.

The FDA cited several reasons for the classification. There was insufficient human safety data. The agency raised immunogenicity concerns, noting the absence of data characterizing human immune response to the peptide. Reviewers also found inconsistent impurity profiles across submitted certificates of analysis. Two nomination packages contained COAs for BPC-157 acetate that did not match the substance the sponsors had actually nominated.

BPC-157 was not alone. In late 2023, the FDA categorized 17 popular peptides as Category 2 substances. TB-500 (a fragment of thymosin beta-4) and Epitalon were among them.

What Category 2 Means in Practice

Category 2 does not mean a substance is dangerous. It means the FDA concluded there is insufficient evidence to determine whether it is safe for compounding. The distinction matters because the burden of proof falls on the nominators, not on the FDA. Unless someone submits adequate safety data, the substance stays restricted.

The Drug Quality and Security Act Framework

This entire classification system exists under the Drug Quality and Security Act (DQSA), passed by Congress in 2013 after a meningitis outbreak linked to contaminated compounded medications killed 76 people. The DQSA created two tracks for compounding pharmacies: Section 503A covers traditional pharmacies compounding for individual prescriptions, and Section 503B covers outsourcing facilities that produce larger batches without individual prescriptions.

Both sections require that compounded drugs use bulk drug substances that are either components of FDA-approved drugs, appear on the relevant bulk drug substances list, or meet specific USP monograph criteria. BPC-157 has no FDA-approved drug product, no USP monograph, and was not on the bulk drug substances list. It existed in a gray area that the Category 2 designation formally closed.

Political Intervention and the PCAC Vote

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced plans to reverse the Category 2 classifications for several peptides, including BPC-157. He framed the original designations as regulatory overreach that harmed patients by pushing them toward unregulated sources. In April 2026, the FDA removed BPC-157 from the Category 2 list.

Then in July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) convened at the White Oak campus. BPC-157 was the first substance the committee addressed. After two days of deliberation, the PCAC voted 8 to 6 to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List, which would allow state-licensed compounding pharmacies to use it in patient prescriptions.

However, we should note a critical distinction: the PCAC vote is a recommendation to the FDA, not a final decision. The FDA retains authority over whether BPC-157 is formally added to the 503A list. In its briefing document, FDA staff stated there is a "lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for ulcerative colitis." As of this writing, the FDA has not issued a final ruling.

What "Research Use Only" Means Legally

Throughout these regulatory shifts, BPC-157 has remained available from research chemical suppliers labeled "for research use only" or "not for human consumption." This labeling is a legal disclaimer, not a scientific designation. It allows suppliers to sell the peptide without FDA approval by positioning it outside the drug regulatory framework.

The legal reality is more complicated. If a supplier markets a peptide with claims about human health effects, the FDA can classify it as an unapproved drug regardless of the label. The FTC can pursue deceptive advertising claims. And buyers who inject a research chemical into their bodies are assuming all risk with no regulatory safety net.

Impact on Availability

The practical effect of these regulatory changes has been uneven. During the Category 2 period (late 2023 through early 2026), compounding pharmacies that had been producing BPC-157 for clinical patients stopped. Some clinicians shifted to prescribing from overseas pharmacies or directing patients to research chemical suppliers, which we found created quality and consistency concerns.

The removal from Category 2 and the positive PCAC vote have created optimism among practitioners, but the pipeline remains incomplete. Until the FDA issues a final rule, compounding pharmacies operate in regulatory uncertainty. Some have resumed production under the assumption that the PCAC recommendation will be formalized. Others are waiting.

For consumers, the situation has not fundamentally changed. BPC-157 is not an approved drug. It cannot be legally marketed for human therapeutic use. It can be prescribed by physicians who use it off-label through compounding, but only if a compounding pharmacy is willing to produce it, and that willingness depends on how each pharmacy reads the current regulatory signals.

If you are considering BPC-157, we recommend working with a licensed healthcare provider who can navigate the current regulatory landscape, source from verified compounding pharmacies, and monitor your response. The regulatory picture is clearer than it was in 2024, but it is not resolved. For vendors we have reviewed that supply research-grade peptides, see our purchasing guide.